. . . . . . . . . "Humans and other mammals"@en . . . . . . . . . "Schmutz, J. and Hunziker, F.; US. Patent 3,539,573; November 10, 1970 ."@en . . . . . . . . . . . "Clozapine"@en . . . . . "Clozapine"@en . "A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem]"@en . . . . . . "Clozapin"@en . "Approximately 50% of the administered dose is excreted in the urine and 30% in the feces."@en . . "Clozapina"@en . "approved"@en . . . "8 hours (range 4-12 hours)"@en . " "@en . "Take without regard to meals."@en . . . . "Clozapine carries a black-box warning for agranulocytosis."@en . . . . . . . . "Clozapinum"@en . "Clozapine's antipsychotic action is likely mediated through a combination of antogistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex. D2 antagonism relieves positive symptoms while 5-HT2A antagonism alleviates negative symptoms."@en . . . . . . . . . . . . . . . . "Limit caffeine intake (may reduce clozapine matabolism)."@en . . . . . . . . . . "Rapid and almost complete"@en . . . . . . . . "Avoid alcohol."@en . . . . . . . . . . . . . . . "5786-21-0"@en . . . . . . . . "97% (bound to serum proteins)"@en . . . "# Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8515788 # Vaddadi KS, Soosai E, Vaddadi G: Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol. 2003 Mar;55(3):307-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12630982 # Naheed M, Green B: Focus on clozapine. Curr Med Res Opin. 2001;17(3):223-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11900316 # Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999 Jan;60(1):36-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10074876"@en . . "For use in patients with treatment-resistant schizophrenia."@en . . . .